Overview
- Sanofi raised its full-year sales forecast after Dupixent sales jumped about 38% to €5.15 billion and the company said operating income should grow slightly faster than sales.
- Sanofi's newly installed CEO Belen Garijo has overhauled the leadership team, named a new head of R&D, and stopped development of several late-stage programs including amlitelimab, itepekimab, and balinatunfib as part of a strategic review.
- Regeneron beat analyst estimates for the quarter with revenue of $4.29 billion and non-GAAP earnings of $14.29 per share, driven by Dupixent strength and a 52% rise in U.S. sales of high-dose Eylea.
- Regeneron said it fully repaid the Sanofi Development Balance, which removes an outstanding collaboration payment, tightens margins and simplifies future financial flows between the partners.
- Analysts and both companies say Dupixent will remain the main growth engine with projections toward roughly €24–25 billion in annual sales by 2030, a reality that is letting Sanofi focus acquisitions and R&D on immunology, rare diseases, and vaccines while changing how it judges late-stage projects.